US20150018705A1 - Neural analysis and treatment system - Google Patents
Neural analysis and treatment system Download PDFInfo
- Publication number
- US20150018705A1 US20150018705A1 US14/330,712 US201414330712A US2015018705A1 US 20150018705 A1 US20150018705 A1 US 20150018705A1 US 201414330712 A US201414330712 A US 201414330712A US 2015018705 A1 US2015018705 A1 US 2015018705A1
- Authority
- US
- United States
- Prior art keywords
- patient
- neural
- aeeg
- sef
- reeg
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000001537 neural effect Effects 0.000 title claims abstract description 88
- 238000004458 analytical method Methods 0.000 title claims abstract description 47
- 238000000537 electroencephalography Methods 0.000 claims abstract description 70
- 238000005259 measurement Methods 0.000 claims abstract description 26
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 22
- 230000003595 spectral effect Effects 0.000 claims abstract description 17
- 230000001054 cortical effect Effects 0.000 claims description 29
- 238000000034 method Methods 0.000 claims description 23
- 230000006978 adaptation Effects 0.000 claims description 18
- 238000011161 development Methods 0.000 claims description 7
- 230000018109 developmental process Effects 0.000 claims description 7
- 230000004641 brain development Effects 0.000 claims description 6
- 230000000926 neurological effect Effects 0.000 claims description 3
- 230000006399 behavior Effects 0.000 claims description 2
- 230000000638 stimulation Effects 0.000 description 52
- 230000000694 effects Effects 0.000 description 28
- 230000003238 somatosensory effect Effects 0.000 description 16
- 210000004556 brain Anatomy 0.000 description 11
- 230000035800 maturation Effects 0.000 description 11
- 238000012545 processing Methods 0.000 description 11
- 230000008569 process Effects 0.000 description 9
- 230000006870 function Effects 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 7
- 229920001296 polysiloxane Polymers 0.000 description 7
- 230000003461 thalamocortical effect Effects 0.000 description 7
- 230000007177 brain activity Effects 0.000 description 6
- 238000001228 spectrum Methods 0.000 description 6
- 230000002123 temporal effect Effects 0.000 description 6
- 230000001953 sensory effect Effects 0.000 description 5
- 238000004891 communication Methods 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 230000002028 premature Effects 0.000 description 4
- 230000000541 pulsatile effect Effects 0.000 description 4
- 230000008521 reorganization Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 210000004885 white matter Anatomy 0.000 description 4
- 206010010904 Convulsion Diseases 0.000 description 3
- 206010022840 Intraventricular haemorrhage Diseases 0.000 description 3
- 208000029028 brain injury Diseases 0.000 description 3
- 230000002490 cerebral effect Effects 0.000 description 3
- 210000004720 cerebrum Anatomy 0.000 description 3
- 230000002596 correlated effect Effects 0.000 description 3
- 230000001351 cycling effect Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000001103 thalamus Anatomy 0.000 description 3
- 241000282412 Homo Species 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 210000000133 brain stem Anatomy 0.000 description 2
- 210000001638 cerebellum Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000001149 cognitive effect Effects 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000002598 diffusion tensor imaging Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000035611 feeding Effects 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- VBCVPMMZEGZULK-NRFANRHFSA-N indoxacarb Chemical compound C([C@@]1(OC2)C(=O)OC)C3=CC(Cl)=CC=C3C1=NN2C(=O)N(C(=O)OC)C1=CC=C(OC(F)(F)F)C=C1 VBCVPMMZEGZULK-NRFANRHFSA-N 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 230000023105 myelination Effects 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 230000001123 neurodevelopmental effect Effects 0.000 description 2
- 230000003534 oscillatory effect Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000002688 persistence Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- 230000002739 subcortical effect Effects 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 230000001360 synchronised effect Effects 0.000 description 2
- 230000000542 thalamic effect Effects 0.000 description 2
- 206010008805 Chromosomal abnormalities Diseases 0.000 description 1
- 208000031404 Chromosome Aberrations Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 208000012239 Developmental disease Diseases 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 241000289581 Macropus sp. Species 0.000 description 1
- 238000007476 Maximum Likelihood Methods 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 206010028182 Multiple congenital abnormalities Diseases 0.000 description 1
- 206010051606 Necrotising colitis Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 229920002319 Poly(methyl acrylate) Polymers 0.000 description 1
- 206010036590 Premature baby Diseases 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 208000005248 Vocal Cord Paralysis Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000005821 brain abnormality Effects 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 210000003618 cortical neuron Anatomy 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 238000013523 data management Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000005857 detection of stimulus Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 210000003194 forelimb Anatomy 0.000 description 1
- 210000005153 frontal cortex Anatomy 0.000 description 1
- 230000003371 gabaergic effect Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 210000004884 grey matter Anatomy 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 208000018773 low birth weight Diseases 0.000 description 1
- 231100000533 low birth weight Toxicity 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 238000002582 magnetoencephalography Methods 0.000 description 1
- 238000002078 massotherapy Methods 0.000 description 1
- 230000018984 mastication Effects 0.000 description 1
- 238000010077 mastication Methods 0.000 description 1
- 230000001785 maturational effect Effects 0.000 description 1
- 210000000412 mechanoreceptor Anatomy 0.000 description 1
- 108091008704 mechanoreceptors Proteins 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 208000004995 necrotizing enterocolitis Diseases 0.000 description 1
- 210000000478 neocortex Anatomy 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 230000008904 neural response Effects 0.000 description 1
- 230000003188 neurobehavioral effect Effects 0.000 description 1
- 230000002863 neuromagnetic effect Effects 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 210000000869 occipital lobe Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 238000000059 patterning Methods 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 201000006195 perinatal necrotizing enterocolitis Diseases 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 201000008752 progressive muscular atrophy Diseases 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000008132 psychomotor development Effects 0.000 description 1
- 210000002804 pyramidal tract Anatomy 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000000988 reflection electron microscopy Methods 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000001020 rhythmical effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 238000012421 spiking Methods 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000012384 transportation and delivery Methods 0.000 description 1
- 210000003901 trigeminal nerve Anatomy 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 230000036266 weeks of gestation Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/24—Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
- A61B5/316—Modalities, i.e. specific diagnostic methods
- A61B5/369—Electroencephalography [EEG]
- A61B5/377—Electroencephalography [EEG] using evoked responses
-
- A61B5/0484—
-
- A61B5/048—
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/24—Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
- A61B5/316—Modalities, i.e. specific diagnostic methods
- A61B5/369—Electroencephalography [EEG]
- A61B5/372—Analysis of electroencephalograms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/24—Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
- A61B5/316—Modalities, i.e. specific diagnostic methods
- A61B5/369—Electroencephalography [EEG]
- A61B5/372—Analysis of electroencephalograms
- A61B5/374—Detecting the frequency distribution of signals, e.g. detecting delta, theta, alpha, beta or gamma waves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/24—Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
- A61B5/316—Modalities, i.e. specific diagnostic methods
- A61B5/369—Electroencephalography [EEG]
- A61B5/377—Electroencephalography [EEG] using evoked responses
- A61B5/383—Somatosensory stimuli, e.g. electric stimulation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4836—Diagnosis combined with treatment in closed-loop systems or methods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4848—Monitoring or testing the effects of treatment, e.g. of medication
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
- A61B5/7235—Details of waveform analysis
- A61B5/7242—Details of waveform analysis using integration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B2503/00—Evaluating a particular growth phase or type of persons or animals
- A61B2503/04—Babies, e.g. for SIDS detection
- A61B2503/045—Newborns, e.g. premature baby monitoring
Definitions
- the present invention generally relates to diagnostic and therapeutic systems, devices, and methods.
- the present invention relates to a neural analysis and treatment system.
- the infant brain is a developing organ of enormous complexity, whose initial form is specified through genetic instruction. It has been shown that pathway formation and network tuning are subsequently modified and continuously refined by experience and activity-dependent mechanisms. For the premature infant, extrauterine life is a pathological condition, and defining normality of electrocortical activity represents a significant challenge in the neonatal intensive care unit.
- Embodiments of the neural analysis and treatment system may provide a solution to conventional EEG systems using a combination of amplitude-integrated electroencephalography (aEEG) as well as range-electroencephalography (rEEG) information to determine one or more neural characteristics of a patient.
- aEEG amplitude-integrated electroencephalography
- rEEG range-electroencephalography
- the neural analysis and treatment system determines certain characteristics of preterm infants that may be used to alter cortical activity of the infant, quantify a spectral edge frequency (SEF) modulation in the EEG spectra, quantify the SEF asymmetry for diagnostic purposes, and quantify and promote cortical adaption.
- SEF spectral edge frequency
- a neural analysis and treatment system includes a computing device with a memory for storing an application that is executable on a processor to receive aEEG and rEEG measurements associated with a patient, determine a spectral edge frequency (SEF) measurement from the received EEG measurements, and determine one or more neural characteristics of the patient according to the determined SEF measurement.
- SEF spectral edge frequency
- FIG. 1A is a block diagram of a computing system that includes a neural analysis and treatment system.
- FIG. 1B depicts an exemplary embodiment of a computing device according to one aspect of the neural analysis and treatment system.
- FIG. 2 is a block diagram of an example computing device that includes a neural analysis and treatment system.
- FIG. 3 is a flowchart depicting a process that may be performed by the neural analysis and treatment application according to an aspect of the neural analysis and treatment system.
- FIG. 4 illustrates example frequency modulated (FM) somatosensory stimulus bursts as presented to the preterm infants through a pneumatically-charged silicone pacifier according to one aspect of the present disclosure.
- FM frequency modulated
- FIG. 5 illustrates an example orocutaneous stimulation schedule that results from the test according to one aspect of the present disclosure.
- FIG. 6 illustrates an example preterm infant with aEEG and pneumatically pulsed stimulation through a regular Philips AVENT BPA-free Soothie silicone pacifier coupled to the digitally-controlled handpiece of the NNS system according to one aspect of the present disclosure.
- FIG. 7 illustrates example bi-hemispheric aEEG sampled from C3-P3 and C4-P4 on a preterm infant according to one aspect of the present disclosure.
- FIG. 8 illustrates example rEEG amplitude bands derived from the left hemisphere EEG (C3-P3) in preterm infants during pulsed orocutaneous and blind pacifier stimulation conditions according to one aspect of the present disclosure.
- FIG. 9 illustrates example rEEG amplitude bands derived from the right hemisphere EEG (C4-P4) in preterm infants during pulsed orocutaneous and blind pacifier stimulation conditions according to one aspect of the present disclosure.
- FIGS. 10A and 10B illustrate mixed model adjusted means, and Post-hoc pairwise comparison.
- G1 NT ‘On’ and Level 3,5,7
- G2 NT ‘On’ and Level 1,2,4,6,8,9
- G3 NT ‘Off’ and Level 3,5,7
- G4 NT ‘Off’ and Level 1,2,4,5,8,9, respectively according to one aspect of the present disclosure.
- FIG. 11 illustrates example rEEG amplitude bands derived from the crosshead EEG montage (P3-P4) in preterm infants during pulsed orocutaneous and blind pacifier stimulation conditions according to one aspect of the present disclosure.
- FIG. 12 is a chart illustrating aEEG data (maxima, mean, and minima) sampled from the left hemisphere (C3-P3) in preterm infants during pulsed orocutaneous (NT ‘ON’) and blind pacifier (PACIFIER only) stimulation conditions.
- FIG. 13 is a chart illustrating aEEG data (maxima, mean, and minima) sampled from the right hemisphere (C4-P4) in preterm infants during pulsed orocutaneous (NT ‘ON’) and blind pacifier (PACIFIER only) stimulation conditions.
- the amplitude-integrated electroencephalogram also known as the cerebral function monitor (CFM)
- CFM cerebral function monitor
- the dual-channel aEEG is typically recorded from two pairs of surface electrodes (e.g., C3-P3, C4-P4) situated on the scalp over the frontoparietal cortices, and proximal to forelimb and orofacial sensorimotor cortical representations.
- the aEEG can be recorded in newborns at all maturational levels, including extremely preterm infants (e.g., from 28 weeks of gestation), and the electrode montage may be left in position over relatively long periods encompassing hours or days.
- the main features extracted from the aEEG include type of background activity, such as discontinuous/continuous activity, interburst intervals or burst rate, cyclic variation in the background activity corresponding to sleep-wake cycling (SWC), upper and lower amplitude margins, amplitude bandwidth, spectral composition, and the presence of seizure patterns.
- type of background activity such as discontinuous/continuous activity, interburst intervals or burst rate, cyclic variation in the background activity corresponding to sleep-wake cycling (SWC), upper and lower amplitude margins, amplitude bandwidth, spectral composition, and the presence of seizure patterns.
- aEEG measurements have been increasingly used in monitoring brain activity of preterm infants.
- the aEEG measurements have also provided normative data on brain maturation in preterm infants at various gestational age (GA) and postmenstrual age (PMA).
- GA gestational age
- PMA postmenstrual age
- neural characteristics including but not limited to aEEG characteristics in preterm infants, including voltages, continuity, and sleep-wake cycling, mature with increasing GA and PMA.
- GA gestational age
- PMA postmenstrual age
- aEEG characteristics mature predominantly with PMA. For example, sleep state differentiation appears in neurologically normal infants at 27-29 weeks PMA. The presence of sleep-wake cycling in preterm infants is strongly associated with good long-term prognosis and is absent in most infants with severe intraventricular hemorrhage (IVH). Long-term outcome can be predicted by aEEG/EEG with 75-80% accuracy at 24 postnatal hours in very preterm infants (e.g., 28 to 32 weeks GA), and in infants with no early indication of brain injury.
- aEEG/rEEG maps developmental features of maturation (e.g., continuity, amplitude margins, amplitude bands, and the like) and/or pathologic brain activity (e.g., seizures, discontinuity, and the like).
- pathologic brain activity e.g., seizures, discontinuity, and the like.
- stimulation of the nervous system plays an important role in brain development and neurodevelopmental outcome. For example, brief, tactile stimulation can be applied to the hand (palm) and foot (sole) to evoke EEG and aEEG activity in extremely low birth weight infants (e.g., infants 24-28 weeks GA with EEG recorded at 30-32 weeks PMA).
- an infant can be instrumented for aEEG and receive, on average, 17 minutes of whole body massage therapy performed 30 minutes after feeding.
- the amplitude of the aEEG trend significantly increased during massage, and also increased the dominant frequency 6 waves which returned to baseline after treatment.
- the spectral signature of brain activity including exogenous and autogenic frequency modulation (i.e., neonate state changes, external stimulation) and rhythmic electrocortical activity (resting state network dynamics) provides the clinician and neuroscientist with a window into the integrity and maturation of the human nervous system in the frequency domain.
- Spectral measures extracted from the EEG reflect complex processes related to cerebral and subcortical maturation and activity and experience dependent change.
- Subcortical inputs from brainstem and thalamus provide an essential source of patterned activity to the developing neocortex. It is thought that disruption of the thalamocortical system, correlated in EEG progression, represents a major component of preterm brain injury.
- Spectral measures have found application in identifying brain pathology.
- spectral power of low frequencies (6 waves; 0-4 Hz) differs significantly between burst episodes of healthy and asphyxiated infants, and has been negatively correlated to the degree of white matter injury on MRI in premature infants.
- Diffusion tensor imaging revealed that thalamocortical connectivity (between thalamus and frontal cortices, supplementary motor areas, occipital lobe, and temporal gyri) is significantly diminished in preterm infants.
- the anatomical findings were corroborated by hemodynamic measures of functional connectivity (fcMRI) showing that very preterm infants scanned at term equivalent age exhibit reduced connectivity between cerebral cortex and thalamus relative to full-term controls.
- thalamocortical activity negatively impacts neurodevelopmental outcome.
- resting cortical activity is characterized by a distinct spectral peak in the alpha frequency range (8-13 Hz). Slowing of this oscillatory peak toward the upper theta-band (6-8 Hz) has been associated with a variety of neurological and neuropsychiatric conditions, and is attributed to altered thalamocortical dynamics.
- the importance of thalamic input on the generation of cortical oscillatory activity is of high importance for cognitive and perceptual processing.
- MEG magnetoencephalography
- FIGS. 1A and 1B depict an example neural analysis and treatment system 100 according to aspects of the disclosure.
- the system 100 includes a neural analysis and treatment computing device 102 or other computing device or system that includes a neural analysis and treatment application 104 and a data source 106 .
- the application 104 receives aEEG and rEEG measurements of a patient 110 , such as from an EEG sensor 112 , and processes the aEEG and rEEG measurements to generate enhanced diagnostics for the patient 110 .
- the application 104 uses the generated diagnostics to develop a therapeutic plan, which may be, for example, a non-nutritive suck entrainment system (NNS) 108 that provides therapeutic stimulus to the patient.
- NPS non-nutritive suck entrainment system
- a range-EEG (rEEG) value which is calculated as the difference between maximum and minimum values for adjacent 2-second intervals from the raw EEG signal, may be used in conjunction with aEEG values for enhanced analysis of standardized normal assessments.
- the rEEG represents a less conservative estimate of peak-to-peak amplitude derived from raw EEG.
- the system 100 provides a method for altering cortical activity. In another embodiment, the system 100 provides a method for quantifying the SEF modulation in the EEG spectra for diagnostic uses. In yet another embodiment, the system 100 provides a method of quantifying SEF asymmetry for diagnostic purposes. In yet another embodiment, the system 100 provides a method to quantify and promote cortical adaptation.
- the rEEG-values are determined for each 2-second interval, linearly connected, and resampled at 8 Hz to provide a continuous signal using the same frequency that is used for storing and displaying aEEG on a BRM3 monitor or equivalent cribside EEG monitoring system (Natus NicONE monitor). Based on rEEG results, five amplitude bands that are designated A through E, are calculated to reflect the relative contribution of different rEEG values.
- the boundaries for the five amplitude bands include A [0-10 microvolts], B [10-25 microvolts], C [25-50 microvolts], D [50-100 microvolts], and E [greater than 100 microvolts], and are expressed as the percentage of time each amplitude band appeared in a given 1 minute epoch (See FIG. 8 ).
- peak-to-peak amplitude (ppA) measures of aEEG and rEEG assessed in 26 extremely preterm infants were strongly associated with PMA, with rEEG showing more distinct patterns. There was a tendency for the representation of low voltages to increase while higher voltages decreased with increasing PMA, accompanied by a prominent increase in rEEG band C.
- the computing device 102 includes a processing system 202 , as shown in FIG. 2 , that executes the neural analysis and treatment application 104 stored in volatile and/or non-volatile memory 204 (i.e., computer readable media) using the data source 106 .
- Examples of such a computing device 102 includes one or more servers, personal computers, mobile computers and/or other mobile devices, and other computing devices.
- the computing device 102 may communicate via wireless and/or wireline communications.
- the data source 106 stores patient data 130 including information associated with the patient. Although the data source 106 is shown as being located on, at, or within the computing device 102 , it is contemplated that the data source 106 can be located remotely from the computing device 102 in other aspects of the system 100 , such as on, at, or within a database of a data management system or a database of another computing device or system having at least one processor and volatile and/or non-volatile memory.
- FIG. 2 also provides a block diagram of an embodiment of a neural analysis and treatment application 104 that can be executed on the computing device 102 .
- the neural analysis and treatment computing device 102 includes a processing system 202 that includes one or more processors or other processing devices.
- a processor is hardware.
- the processing system 202 executes the neural analysis and treatment application 104 to provide one or more neural analysis and/or entrainment procedures, such as altering cortical activity, quantifying and promoting cortical adaptation of the patient, quantifying SEF modulation in the EEG spectra for diagnostic uses, and/or quantifying SEF asymmetry for diagnostic purposes.
- the neural analysis and treatment computing device 102 includes a computer readable media 204 on which the neural analysis and treatment application 104 and data source 106 are stored.
- the neural analysis and treatment application 104 includes instructions or modules that are executable by the processing system 202 to perform the features of the application 104 described herein.
- the computer readable media 204 may include volatile media, nonvolatile media, removable media, non-removable media, and/or another available media that can be accessed by the neural analysis and treatment computing device 102 .
- computer readable media 204 comprises computer storage media and communication media.
- Computer storage media includes non-transient storage memory/media, volatile media, nonvolatile media, removable media, and/or non-removable media implemented in a method or technology for storage of information, such as computer/machine readable/executable instructions, data structures, program modules, and/or other data.
- Communication media may embody computer readable instructions, data structures, program modules, or other data and include an information delivery media or system.
- An EEG interface module 206 receives patient information about the patient 110 , such as aEEG and rEEG information associated with the patient's brainwaves.
- the EEG sensor 112 includes its own computing device such that the EEG interface module 206 communicates with the EEG sensor 112 via wireless and/or wireline communications. That is, the computing device of the EEG sensor 112 may have one or more processors and volatile and/or non-volatile memory. Examples of such a remote computing device may include one or more personal computers, mobile computers and/or other mobile devices, and other computing devices.
- the EEG interface module 206 may receive patient information directly using telemetry information from sensors configured in the NNS entrainment system 108 or a module thereof.
- An NNS entrainment system interface module 207 communicates with the NNS entrainment system 108 to assess and entrain brain activity for controlling respiration, mastication, or other neuromuscular functions of the patient. Additional details related to the NNS entrainment system 108 are disclosed in U.S. patent application Ser. No. 13/457,059, entitled “Enhanced therapeutic stimulus system and methods of use,” filed Apr. 26, 2012; U.S. patent application Ser. No. 13/457,203, entitled “Enhanced Therapeutic Stimulus For Non-Nutritive Suck Entrainment System and Method,” filed Apr. 26, 2012; and U.S. patent application Ser. No.
- aEEG/rEEG analysis system is described herein for use with an NNS device or the NNS entrainment system 108 , it should be understood that that the aEEG/rEEG analysis system may be used with any other system that performs a therapeutic plan on the patient using processed EEG data.
- An aEEG/rEEG processing module 208 generates aEEG and rEEG information from patient information gathered by the EEG interface module 206 .
- the aEEG/rEEG processing module 208 generates the aEEG and rEEG information from raw EEG data obtained from the EEG interface module 206 .
- the aEEG/rEEG processing module 208 processes aEEG/rEEG information generated by the EEG sensor 112 .
- a treatment development module 210 develops a therapeutic plan to be used by the NNS entrainment system 108 for correcting and otherwise alleviating an abnormality of the patient 110 .
- the treatment development module 210 develops an entrainment procedure for training certain brainwave behavior in the patient.
- the treatment development module 210 may develop a therapeutic plan or protocol to alter cortical activity of the patient 110 .
- the treatment development module 210 may develop a therapeutic plan to quantify and promote cortical adaptation of the patient.
- a neural analysis module 212 generates one or more reports that may be used by personnel, including researchers and healthcare providers, among others, for determining one or more conditions associated with the patient 110 .
- the neural analysis module 212 may quantify SEF modulation in the EEG spectra of the received aEEG/rEEG information for diagnostic uses.
- the neural analysis module 212 may quantify SEF asymmetry of the aEEG/rEEG information for diagnostic purposes.
- a NNS management module 214 manages the overall operation of the NNS entrainment system 108 .
- the NNS management module 214 generates a graphical user interface (GUI) 220 that displays various activities and provides for administrative control of the NNS entrainment system 108 from the neural analysis and treatment computing device 102 .
- GUI graphical user interface
- the GUI 220 may display operating characteristics of the NNS entrainment system 108 and receive user input via an input device 222 for controlling the operation of the NNS entrainment system 108 .
- modules described herein are provided only as an example of a computing device that may execute the neural analysis and treatment application 104 according to the teachings of the present invention, and that other computing devices may have the same modules, different modules, additional modules, or fewer modules than those described herein.
- one or more modules as described in FIG. 2 may be combined into a single module.
- certain modules described herein may be encoded and executed on other computing devices, such as the computing device configured in the NNS entrainment system 108 .
- one or more of the modules may be stored and executed by the neural analysis and treatment computing device 102 , where data and instructions are transmitted to and from the neural analysis and treatment computing device 102 and the computing device of the NNS entrainment system 108 to execute their functions.
- FIG. 3 illustrates an example process that may be performed by the neural analysis and treatment application 104 according to the teachings of the present disclosure.
- the application 104 receives EEG/aEEG/rEEG information associated with a patient.
- the EEG/aEEG/rEEG information may be obtained from any suitable source, such as an EEG sensor that obtains aEEG/rEEG information of a preterm infant.
- the neural analysis and treatment application 104 generates the aEEG and rEEG information from raw EEG data obtained from the EEG sensor 112 .
- the neural analysis and treatment application 104 processes aEEG/rEEG information that has been generated by the EEG sensor 112 .
- the application 104 processes the received EEG information.
- the application 104 generates spectral edge frequency (SEF) information from the received EEG/aEEG/rEEG information.
- SEF spectral edge frequency
- Spectral edge frequency typically expressed as SEF-“X,” identifies the frequency below which “X” percent of the total power of a given signal is located.
- SEF-90 is defined as the frequency below which 90% of the power in a spectrum resides. In many cases, SEF-90 measurements are thought to reflect cerebral maturation.
- the observed modulation in the EEG spectra during and after somatosensory stimulation is a reflection of the dynamics of thalamocortical excitation resulting from synchronous volleys of oral mechanoreceptive afferent activity in the maxillary (V2) and mandibular (V3) divisions of the trigeminal nerve evoked by the pulsed pneumatic orocutaneous stimulation.
- V2 maxillary
- V3 mandibular
- the pulsed orocutaneous stimulus delivered to the mechanoreceptor-rich oral apparatus of the preterm infant appears to have ecological validity as a salient sensory input, which also provides a safe and comforting experience for the infant.
- Early experiences such as incorporating gentle approach to care, light dimming, rest periods, flexed position with appropriate support, and kangaroo care, positively alters brain structure and function, including EEG spectral coherence and neurobehavioral functioning.
- Somatosensory stimulation plays an important role in brain function and psychomotor development, and is suggested to minimize the risk of developmental disorders among preterm infants. Massage has been shown to be very beneficial to premature infants.
- spectral EEG measures are also apparent in somatosensory stimulation interventions. For example, skin-to-skin contact accelerates brain maturation in healthy preterm infants resulting in fewer REMs, more quiet sleep, respiratory regularity, longer cycles, and less spectral ⁇ -wave activity.
- the neural analysis and treatment application 104 generates reports that may be used for diagnosing one or more conditions of the patient.
- the application 104 determines a level of asymmetry of the aEEG/rEEG information.
- a challenge in developmental neuroscience is obtaining a complete understanding of structural and functional hemispheric asymmetries in early life.
- a significant asymmetry in cortical SEF measurements during oral somatosensory stimulation among preterm infants recorded at 32 weeks PMA has been seen. Indeed, there is an abundance of experimental evidence to support anatomic and functional cortical asymmetry in early life to account for SEF asymmetry. Macroscopic left-right differences has been shown to be present from the fetal life and onward.
- the developmental time scale may also differ between the cerebral hemispheres.
- Post-mortem studies have shown that the superior frontal gyrus, the superior temporal gyrus, and Heschl's gyrus appear 1 to 2 weeks sooner in the right hemisphere than in the left, whereas other evidence has shown that the plenum temporal and Heschl's gyrus are larger in the left hemisphere in fetuses and infants.
- Gray and white matter volumes in neonates tend to be larger in the left hemisphere, which is opposite that in adults.
- An early rightward morphological asymmetry in the fetal brain during the third trimester, and a right temporal sulcus larger than the left has also been reported.
- the neural analysis and treatment application 104 develops a therapeutic plan for the patient.
- the application 104 develops a therapeutic plan to provide cortical adaptation for the patient 110 .
- Adaptation refers to response attenuation in response to repeated stimulation. Adaptation has many forms (short-term and long-term) and is apparent in the periphery at the mechanosensitive nerve ending, within spinal cord, brainstem, and thalamic subnuclei, and finally among vast arrays of local circuits within the primary (S1) and secondary (S2) somatosensory cortices. Cortical adaptation to sustained sensory input is regarded as one of the most ubiquitous forms of short-term plasticity.
- Neural adaptation can be observed in either the amplitude or frequency domain. In terms of frequency-following capabilities, the rate of neural response adaptation tends to increase as one proceeds from the periphery to the S1/S2 cortex. For example, using the same pulsed pneumatic orocutaneous stimulus with a Soothie® silicone pacifier provide cortical adaptation in neuromagnetic response magnitude in S1 and S2 in young adults.
- a significant after-effect or persistence in SEF adaptation was observed in the preterm infants who received the pulsed orocutaneous stimulation.
- Use of a controlled somatosensory inputs reveal the emergence of cortical adaptation may serve as a biomarker of brain maturation.
- sustained sensory stimulation leads to transformations in the thalamocortical encoding that impact the nature of information conveyed about the sensory stimuli.
- Changes in mid-layer cortical neuron spiking activity reflect a switch in their role with adaptation, from coincidence detectors (tuned for stimulus detection in a non-adapted state) to integrators (tuned for stimulus discrimination after adaptation).
- a dynamic cortical inhibitory mechanism shapes the initial activity into a stimulus-specific spatial pattern of columnar assemblies. Lateral interactions between adjacent columns are the result of intrinsic inhibitory (GABA-ergic) and excitatory effects (glutamate) which lead to a differential modification (across columns) of the membrane potential that can last for as long as several seconds.
- Study infants were randomly assigned to two groups, including those who received pulsed orocutaneous stimulation (Treatment group), and those who did not (Control group).
- Parents were consented in accordance with the Santa Clara Valley Medical Center Human Subjects Institutional Review Board approval.
- Inclusion criteria included those infants having a gestational age of 24-32 weeks, and at least 28 weeks post-menstrual age at the time of enrollment.
- Exclusion criteria included those infants having chromosomal abnormalities, multiple congenital anomalies, or any major congenital anomalies. Infants with history of severe IVH, necrotizing enterocolitis (e.g., greater than stage III), vocal cord paralysis, seizures, and meningitis, or nippling all feeds at the time of enrollment.
- the primary goal was to determine the effects of highly controlled (pneumatic servo) pulsed orocutaneous stimulation presented during gavage feedings begun at 32 weeks PMA on the modulation of aEEG/rEEG activity in the amplitude domain among medically stable preterm infants monitored in the neonatal intensive care unit (NICU).
- highly controlled (pneumatic servo) pulsed orocutaneous stimulation presented during gavage feedings begun at 32 weeks PMA on the modulation of aEEG/rEEG activity in the amplitude domain among medically stable preterm infants monitored in the neonatal intensive care unit (NICU).
- the stimulation was delivered by a servo-controlled pneumatic amplifier (NTrainer System®, Innara HealthTM, Shawnee, Kans. USA) specially designed to transmit repeating pneumatic pulse trains to the soft tissues of the infant's lips-anterior tongue-intraoral mucosa-jaw through a regular (green) SoothieTM silicone pacifier.
- This 6-cycle orocutaneous stimulus burst was frequency modulated, consisting of sequential cycle periods of 510, 526, 551, 580, and 626 milliseconds with an intertrain interval of 2 seconds.
- FIG. 4 illustrates example frequency modulated (FM) somatosensory stimulus bursts as presented to the preterm infants through a pneumatically-charged silicone pacifier. Each burst consists of 6 pulses followed by a 2-second pause period.
- a servo-controlled microprocessor provides the gating function (top panel) to dynamically ‘charge’ the intraluminal pressure of the silicone pacifier (middle panel) resulting in rapid conformational changes in pacifier geometry (bottom panel).
- the peak-to-peak displacements associated with these pneumatically charged transitions in the intraluminal pressure is approximately 400 microns with a 10-90% rise/fall time of 31 milliseconds.
- the spatiotemporal features of this somatosensory stimulus mimics the synchronous volleys of afference associated with ororhythmic patterning, and thus constitutes an approximation to a physiologically salient somatosensory experience normally encoded by the trigeminal system.
- the pressure rise-fall time (10-90% intercepts) of each 50 millisecond pulse was 31 milliseconds, and the resultant displacement at the pacifier-lip/tongue tissue interface was approximately 400 microns.
- Three-minute pneumatic orocutaneous stimulation periods were interleaved with 5.5 minute pause periods, where the pacifier was removed from the infant's mouth.
- FIG. 5 illustrates an example orocutaneous stimulation schedule that results from the test.
- Nine sequential data blocks are indicated by P1 through P9 spanning 32 minutes.
- the pulsed orocutaneous stimulus (NT Stimulus) or the blind ‘sham’ pacifier are presented to the infant during periods P3, P5, and P7.
- the pacifier apparatus was removed from the baby's mouth during periods P1, P2, P4, P6, P8, and P9.
- the control infants received a sham stimulation program in which infants were offered the same type of Soothie pacifier without patterned stimulation (blind pacifier).
- the staging of a single stimulation session was given concurrently with gavage (e.g., tube-feeding). Up to three such sessions were administered to preterm infants per day according to their 3-hour feed cycles. Infants were swaddled with limbs at midline, and in a quiet-awake to drowsy state during stimulation.
- EEG signals were recorded on a BRM3 monitor for up to 4-days beginning at approximately 32 weeks PMA.
- FIG. 6 illustrates an example preterm infant with aEEG and pneumatically pulsed stimulation through a regular Philips AVENT BPA-free Soothie silicone pacifier coupled to the digitally-controlled handpiece of the NTrainer System®.
- EEG signals derived from hydrogel electrodes placed at C3-P3 and C4-P4 were recorded on a bedside aEEG monitor.
- the right- and left-side EEG signals were amplified by a factor of approximately five thousand and bandpass-filtered (e.g., first-order high-pass filter at (f, ⁇ 3 dB @ 1 Hz) and a fourth-order low-pass Butterworth at (f, ⁇ 3 dB @ 50 Hz)), and digitized at a sampling rate of 256 Hz.
- bandpass-filtered e.g., first-order high-pass filter at (f, ⁇ 3 dB @ 1 Hz) and a fourth-order low-pass Butterworth at (f, ⁇ 3 dB @ 50 Hz)
- a sampling rate of 256 Hz e.g., Brainz Analyze Research (v1.5) software was used to derive the aEEG maxima/mean/minima, and rEEG amplitude bands (A [0-10 microvolts), B [10-25 microvolts], C [25-50 microvolts], D [50-100 microvolts], and E [>100 micro
- mixed models for repeated measures were used to compare the aEEG and rEEG amplitude measures between four stimulus conditions, including (1) NT ‘ON’ pacifier+pneumatic pulse, (2) NT ‘ON’ control epochs, (3) NT ‘OFF’ blind ‘sham’ pacifier, and (4) NT ‘OFF’ control epochs.
- Mixed models estimated the stimulus effect on each outcome via the use of restricted maximum likelihood estimator and compound symmetric error covariance structure. When the stimulus effect was significant at 0.05 alpha level, pair-wise comparisons of adjusted means were performed using a Bonferroni-corrected p-value. All analyses were conducted using SAS 9.3.
- FIG. 7 illustrates example bi-hemispheric aEEG sampled from C3-P3 and C4-P4 on a preterm infant (32 wks PMA).
- Indexed events (#56, 58, and 60) represent the onset of 3-minute pulsed orocutaneous stimulation periods interleaved with 5.5 minute no-stimulus periods. As shown, aEEG amplitude modulation is present in the electrophysiological record during somatosensory stimulation. Indexed events at 56, 58, and 60 represent the onset of 3-minute pulsed orocutaneous stimulation periods interleaved with 5.5 minute no-stimulus periods. During pulsed somatosensory stimulation, aEEG modulation at the lower and upper amplitude margins of the electrophysiological record was also present.
- stimulus condition yielded significant main effects for aEEG maxima, mean, and minima in the left hemisphere (p ⁇ 0.0001), and significant main effects for aEEG maxima and mean in the right hemisphere.
- Stimulus condition was also a significant main effect for the crosshead measures of aEEG maxima and mean.
- Cortical response asymmetry during patterned orocutaneous stimulation was apparent, with the largest changes in aEEG amplitude measures occurring in the left hemisphere.
- the blind pacifier condition yielded an average aEEG maxima in left and right hemisphere of 12.89 microvolts and 12.81 microvolts, respectively, whereas the addition of the patterned orocutaneous stimulation yielded an average aEEG maxima of 11.68 microvolts and 13.38 microvolts, respectively (p ⁇ 0.001).
- the presence of the pulsatile oral somatosensory stimulation distinct from a blind pacifier alone, alters the balance in excitation with significant attenuation of the aEEG in the left hemisphere and facilitation in the right hemisphere.
- FIG. 8 illustrates example rEEG amplitude bands sampled from the left hemisphere (C3-P3) in preterm infants during pulsed orocutaneous and blind pacifier stimulation conditions.
- NT ‘IN’ indicates the pneumatically charged pacifier is in the mouth
- NT ‘OUT’ indicates the charged pacifier is out of the mouth
- BLIND PAC ‘IN’ indicates the regular Soothie pacifier is in the mouth
- BLIND PAC ‘OUT’ indicates the regular Soothie pacifier is out of the baby's mouth.
- FIG. 9 illustrates example rEEG amplitude bands sampled from the right hemisphere (C4-P4) in preterm infants during pulsed orocutaneous and blind pacifier stimulation conditions.
- NT ‘IN’ indicates the pneumatically charged pacifier is in the mouth
- NT ‘OUT’ indicates the charged pacifier is out of the mouth
- BLIND PAC ‘IN’ indicates the regular Soothie pacifier is in the mouth
- BLIND PAC ‘OUT’ indicates the regular Soothie pacifier is out of the baby's mouth.
- FIGS Statistically significant main and pair-wise comparison effects are summarized in FIGS.
- G1 NT ‘On’ and Level 3,5,7
- G2 NT ‘On’ and Level 1,2,4,6,8,9
- G3 NT ‘Off’ and Level 3,5,7
- G4 NT ‘Off’ and Level 1,2,4,5,8,9, respectively.
- FIG. 11 illustrates example rEEG amplitude bands sampled from the crosshead montage (P3-P4) in preterm infants during pulsed orocutaneous and blind pacifier stimulation conditions.
- NT ‘IN’ indicates the pneumatically charged pacifier is in the mouth
- NT ‘OUT’ indicates the pneumatically-charged pacifier is out of the mouth
- BLIND PAC ‘IN’ indicates the regular Soothie pacifier is in the mouth
- BLIND PAC ‘OUT’ indicates the regular Soothie pacifier is out of the baby's mouth.
- the proportion of rEEG adjusted means in the E and C bands for the blind pacifier condition was 32.17% and 17.13%, respectively.
- Preterm infants who received the pulsatile orocutaneous stimulation manifest a significant shift in rEEG power from the E band ( ⁇ 26.36%) to the C band (+24.86%).
- FIG. 12 illustrates Mean aEEG measures (maxima, mean, and minima) sampled from the left hemisphere (C3-P3) in preterm infants during pulsed orocutaneous (NT ‘ON’) and blind pacifier (PACIFIER only) stimulation conditions.
- Mean aEEG measures maximum, mean, and minima sampled from the left hemisphere (C3-P3) in preterm infants during pulsed orocutaneous (NT ‘ON’) and blind pacifier (PACIFIER only) stimulation conditions.
- FIG. 13 illustrates Mean aEEG measures (maxima, mean, and minima) sampled from the right hemisphere (C4-P4) in preterm infants during pulsed orocutaneous (NT ‘ON’) and blind pacifier (PACIFIER only) stimulation conditions.
- Mean aEEG measures maximum, mean, and minima sampled from the right hemisphere (C4-P4) in preterm infants during pulsed orocutaneous (NT ‘ON’) and blind pacifier (PACIFIER only) stimulation conditions.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Surgery (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Artificial Intelligence (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Physiology (AREA)
- Signal Processing (AREA)
- Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
Abstract
Description
- This application claims priority to U.S. Provisional Patent Application No. 61/845,842, filed on Jul. 12, 2013, entitled “Neural Analysis and Treatment System,” and U.S. Provisional Patent Application No. 61/872,236, filed on Aug. 30, 2013, also entitled “Neural Analysis and Treatment System”, the contents of each provisional application including all appendices, is herein incorporated by reference in its entirety.
- The subject matter discussed in this patent application was funded in part by United States Grant No. RO1 DC003311 from the National Institute of Health (NIH). The government may have certain rights to the subject matter discussed herein.
- Not Applicable.
- The present invention generally relates to diagnostic and therapeutic systems, devices, and methods. In particular, the present invention relates to a neural analysis and treatment system.
- The infant brain is a developing organ of enormous complexity, whose initial form is specified through genetic instruction. It has been shown that pathway formation and network tuning are subsequently modified and continuously refined by experience and activity-dependent mechanisms. For the premature infant, extrauterine life is a pathological condition, and defining normality of electrocortical activity represents a significant challenge in the neonatal intensive care unit.
- To address this challenge, reduced-montage electroencephalography is currently used to monitor and map brain maturation and assess neurological status in preterm infants. Therefore, what is needed is a system that provides for enhanced analysis and treatment of preterm infants as well as other types of patients having neural disorders.
- Embodiments of the neural analysis and treatment system may provide a solution to conventional EEG systems using a combination of amplitude-integrated electroencephalography (aEEG) as well as range-electroencephalography (rEEG) information to determine one or more neural characteristics of a patient. In particular, the neural analysis and treatment system determines certain characteristics of preterm infants that may be used to alter cortical activity of the infant, quantify a spectral edge frequency (SEF) modulation in the EEG spectra, quantify the SEF asymmetry for diagnostic purposes, and quantify and promote cortical adaption.
- According to one embodiment, a neural analysis and treatment system includes a computing device with a memory for storing an application that is executable on a processor to receive aEEG and rEEG measurements associated with a patient, determine a spectral edge frequency (SEF) measurement from the received EEG measurements, and determine one or more neural characteristics of the patient according to the determined SEF measurement.
-
FIG. 1A is a block diagram of a computing system that includes a neural analysis and treatment system. -
FIG. 1B depicts an exemplary embodiment of a computing device according to one aspect of the neural analysis and treatment system. -
FIG. 2 is a block diagram of an example computing device that includes a neural analysis and treatment system. -
FIG. 3 is a flowchart depicting a process that may be performed by the neural analysis and treatment application according to an aspect of the neural analysis and treatment system. -
FIG. 4 illustrates example frequency modulated (FM) somatosensory stimulus bursts as presented to the preterm infants through a pneumatically-charged silicone pacifier according to one aspect of the present disclosure. -
FIG. 5 illustrates an example orocutaneous stimulation schedule that results from the test according to one aspect of the present disclosure. -
FIG. 6 illustrates an example preterm infant with aEEG and pneumatically pulsed stimulation through a regular Philips AVENT BPA-free Soothie silicone pacifier coupled to the digitally-controlled handpiece of the NNS system according to one aspect of the present disclosure. -
FIG. 7 illustrates example bi-hemispheric aEEG sampled from C3-P3 and C4-P4 on a preterm infant according to one aspect of the present disclosure. -
FIG. 8 illustrates example rEEG amplitude bands derived from the left hemisphere EEG (C3-P3) in preterm infants during pulsed orocutaneous and blind pacifier stimulation conditions according to one aspect of the present disclosure. -
FIG. 9 illustrates example rEEG amplitude bands derived from the right hemisphere EEG (C4-P4) in preterm infants during pulsed orocutaneous and blind pacifier stimulation conditions according to one aspect of the present disclosure. -
FIGS. 10A and 10B illustrate mixed model adjusted means, and Post-hoc pairwise comparison. G1: NT ‘On’ andLevel Level Level Level -
FIG. 11 illustrates example rEEG amplitude bands derived from the crosshead EEG montage (P3-P4) in preterm infants during pulsed orocutaneous and blind pacifier stimulation conditions according to one aspect of the present disclosure. -
FIG. 12 is a chart illustrating aEEG data (maxima, mean, and minima) sampled from the left hemisphere (C3-P3) in preterm infants during pulsed orocutaneous (NT ‘ON’) and blind pacifier (PACIFIER only) stimulation conditions. -
FIG. 13 is a chart illustrating aEEG data (maxima, mean, and minima) sampled from the right hemisphere (C4-P4) in preterm infants during pulsed orocutaneous (NT ‘ON’) and blind pacifier (PACIFIER only) stimulation conditions. - The amplitude-integrated electroencephalogram (aEEG), also known as the cerebral function monitor (CFM), reflects integrated brain activity and permits time-compressed, continuous bedside electrocortical monitoring. The dual-channel aEEG is typically recorded from two pairs of surface electrodes (e.g., C3-P3, C4-P4) situated on the scalp over the frontoparietal cortices, and proximal to forelimb and orofacial sensorimotor cortical representations. The aEEG can be recorded in newborns at all maturational levels, including extremely preterm infants (e.g., from 28 weeks of gestation), and the electrode montage may be left in position over relatively long periods encompassing hours or days.
- The main features extracted from the aEEG include type of background activity, such as discontinuous/continuous activity, interburst intervals or burst rate, cyclic variation in the background activity corresponding to sleep-wake cycling (SWC), upper and lower amplitude margins, amplitude bandwidth, spectral composition, and the presence of seizure patterns.
- In numerous studies, aEEG measurements have been increasingly used in monitoring brain activity of preterm infants. The aEEG measurements have also provided normative data on brain maturation in preterm infants at various gestational age (GA) and postmenstrual age (PMA). These studies have shown that neural characteristics, including but not limited to aEEG characteristics in preterm infants, including voltages, continuity, and sleep-wake cycling, mature with increasing GA and PMA. For example, with greater GA the relative amount of continuous activity (e.g., aEEG measurements greater than 5.0 microvolts (μV) and maximal amplitude between 20 and 40 microvolts (μV)) tends to increase while discontinuous patterns decrease. The number of bursts per hour decreased with increasing GA. In preterm infants with no evidence of brain abnormalities or injury, aEEG characteristics mature predominantly with PMA. For example, sleep state differentiation appears in neurologically normal infants at 27-29 weeks PMA. The presence of sleep-wake cycling in preterm infants is strongly associated with good long-term prognosis and is absent in most infants with severe intraventricular hemorrhage (IVH). Long-term outcome can be predicted by aEEG/EEG with 75-80% accuracy at 24 postnatal hours in very preterm infants (e.g., 28 to 32 weeks GA), and in infants with no early indication of brain injury.
- Nevertheless, as the utility and scope of aEEG evolves, so does the need for quantitative normal values and standardized signal processing methods. For example, in one particular experiment, reference values of aEEG amplitude margins were obtained for 274 infants with a wide range of PMAs and constituted the basis for the quantitative assessment of aEEG changes with maturation in neonates and young infants. The upper and lower margins of the aEEG in both active and quiet sleep rose in infants after the neonatal period, while the bandwidth defined as a voltage distance between the upper and lower margins of the aEEG decreased monotonically throughout the PMA range from 30 to 55 weeks.
- To date, nearly all studies of preterm brain cortical activity using aEEG/rEEG have been designed to map developmental features of maturation (e.g., continuity, amplitude margins, amplitude bands, and the like) and/or pathologic brain activity (e.g., seizures, discontinuity, and the like). However, it should be recognized that stimulation of the nervous system plays an important role in brain development and neurodevelopmental outcome. For example, brief, tactile stimulation can be applied to the hand (palm) and foot (sole) to evoke EEG and aEEG activity in extremely low birth weight infants (e.g., infants 24-28 weeks GA with EEG recorded at 30-32 weeks PMA). Additionally, an infant can be instrumented for aEEG and receive, on average, 17 minutes of whole body massage therapy performed 30 minutes after feeding. The amplitude of the aEEG trend significantly increased during massage, and also increased the
dominant frequency 6 waves which returned to baseline after treatment. - The spectral signature of brain activity, including exogenous and autogenic frequency modulation (i.e., neonate state changes, external stimulation) and rhythmic electrocortical activity (resting state network dynamics) provides the clinician and neuroscientist with a window into the integrity and maturation of the human nervous system in the frequency domain. Spectral measures extracted from the EEG reflect complex processes related to cerebral and subcortical maturation and activity and experience dependent change. Subcortical inputs from brainstem and thalamus provide an essential source of patterned activity to the developing neocortex. It is thought that disruption of the thalamocortical system, correlated in EEG progression, represents a major component of preterm brain injury. Spectral measures have found application in identifying brain pathology. For example, spectral power of low frequencies (6 waves; 0-4 Hz) differs significantly between burst episodes of healthy and asphyxiated infants, and has been negatively correlated to the degree of white matter injury on MRI in premature infants. Diffusion tensor imaging (DTI) revealed that thalamocortical connectivity (between thalamus and frontal cortices, supplementary motor areas, occipital lobe, and temporal gyri) is significantly diminished in preterm infants. The anatomical findings were corroborated by hemodynamic measures of functional connectivity (fcMRI) showing that very preterm infants scanned at term equivalent age exhibit reduced connectivity between cerebral cortex and thalamus relative to full-term controls.
- The effects of prematurity on the thalamocortical system negatively impacts neurodevelopmental outcome. In neurotypical infants, resting cortical activity is characterized by a distinct spectral peak in the alpha frequency range (8-13 Hz). Slowing of this oscillatory peak toward the upper theta-band (6-8 Hz) has been associated with a variety of neurological and neuropsychiatric conditions, and is attributed to altered thalamocortical dynamics. The importance of thalamic input on the generation of cortical oscillatory activity is of high importance for cognitive and perceptual processing. In a recent study, magnetoencephalography (MEG) was used to measure global spectral activity in 11 school-age children (approximately 7.5 years of age) born very preterm (less than 32 weeks gestation) without major intellectual or neurological impairment, and these children were compared to a group of 11 age-matched full-term controls. The very preterm children exhibited a slowing of peak frequency toward the theta-band over bilateral frontal cortex and a reduction in alpha-band power over bilateral frontal and temporal cortex. It is suggested that mildly dysrhythmic thalamocortical interactions may contribute to altered spontaneous cortical activity in children born very preterm.
-
FIGS. 1A and 1B depict an example neural analysis andtreatment system 100 according to aspects of the disclosure. Thesystem 100 includes a neural analysis andtreatment computing device 102 or other computing device or system that includes a neural analysis andtreatment application 104 and adata source 106. As will be described in detail below, theapplication 104 receives aEEG and rEEG measurements of apatient 110, such as from anEEG sensor 112, and processes the aEEG and rEEG measurements to generate enhanced diagnostics for thepatient 110. Optionally, theapplication 104 uses the generated diagnostics to develop a therapeutic plan, which may be, for example, a non-nutritive suck entrainment system (NNS) 108 that provides therapeutic stimulus to the patient. - According to the teachings of the present disclosure, a range-EEG (rEEG) value, which is calculated as the difference between maximum and minimum values for adjacent 2-second intervals from the raw EEG signal, may be used in conjunction with aEEG values for enhanced analysis of standardized normal assessments. Compared to aEEG, the rEEG represents a less conservative estimate of peak-to-peak amplitude derived from raw EEG.
- In one embodiment, the
system 100 provides a method for altering cortical activity. In another embodiment, thesystem 100 provides a method for quantifying the SEF modulation in the EEG spectra for diagnostic uses. In yet another embodiment, thesystem 100 provides a method of quantifying SEF asymmetry for diagnostic purposes. In yet another embodiment, thesystem 100 provides a method to quantify and promote cortical adaptation. Each of these features of thesystem 100 will be described in detail herein below. - In one particular embodiment, the rEEG-values are determined for each 2-second interval, linearly connected, and resampled at 8 Hz to provide a continuous signal using the same frequency that is used for storing and displaying aEEG on a BRM3 monitor or equivalent cribside EEG monitoring system (Natus NicONE monitor). Based on rEEG results, five amplitude bands that are designated A through E, are calculated to reflect the relative contribution of different rEEG values. In one embodiment, the boundaries for the five amplitude bands include A [0-10 microvolts], B [10-25 microvolts], C [25-50 microvolts], D [50-100 microvolts], and E [greater than 100 microvolts], and are expressed as the percentage of time each amplitude band appeared in a given 1 minute epoch (See
FIG. 8 ). In one particular study, peak-to-peak amplitude (ppA) measures of aEEG and rEEG assessed in 26 extremely preterm infants were strongly associated with PMA, with rEEG showing more distinct patterns. There was a tendency for the representation of low voltages to increase while higher voltages decreased with increasing PMA, accompanied by a prominent increase in rEEG band C. This experiment demonstrates that the variance of log-transformed voltages are correlated with PMA (R2=0.84-0.89), exceeding previous correlations for the lower margin amplitude during quiet sleep (R2=0.75). The rEEG provides a relatively more precise estimate of peak-to-peak amplitude based on the raw EEG tracing when compared with aEEG, correlates strongly with PMA, and may serve as a biomarker for brain maturation and quantification of EEG suppression in brain injury. Incorporating both aEEG and rEEG offer the potential to advance an understanding of brain activity in health and disease among extremely premature infants. - In one embodiment, the
computing device 102 includes aprocessing system 202, as shown inFIG. 2 , that executes the neural analysis andtreatment application 104 stored in volatile and/or non-volatile memory 204 (i.e., computer readable media) using thedata source 106. Examples of such acomputing device 102 includes one or more servers, personal computers, mobile computers and/or other mobile devices, and other computing devices. Thecomputing device 102 may communicate via wireless and/or wireline communications. - The data source 106 stores
patient data 130 including information associated with the patient. Although thedata source 106 is shown as being located on, at, or within thecomputing device 102, it is contemplated that thedata source 106 can be located remotely from thecomputing device 102 in other aspects of thesystem 100, such as on, at, or within a database of a data management system or a database of another computing device or system having at least one processor and volatile and/or non-volatile memory. -
FIG. 2 also provides a block diagram of an embodiment of a neural analysis andtreatment application 104 that can be executed on thecomputing device 102. According to one aspect, the neural analysis andtreatment computing device 102 includes aprocessing system 202 that includes one or more processors or other processing devices. A processor is hardware. Theprocessing system 202 executes the neural analysis andtreatment application 104 to provide one or more neural analysis and/or entrainment procedures, such as altering cortical activity, quantifying and promoting cortical adaptation of the patient, quantifying SEF modulation in the EEG spectra for diagnostic uses, and/or quantifying SEF asymmetry for diagnostic purposes. - The neural analysis and
treatment computing device 102 includes a computerreadable media 204 on which the neural analysis andtreatment application 104 anddata source 106 are stored. The neural analysis andtreatment application 104 includes instructions or modules that are executable by theprocessing system 202 to perform the features of theapplication 104 described herein. - The computer
readable media 204 may include volatile media, nonvolatile media, removable media, non-removable media, and/or another available media that can be accessed by the neural analysis andtreatment computing device 102. By way of example and not limitation, computerreadable media 204 comprises computer storage media and communication media. Computer storage media includes non-transient storage memory/media, volatile media, nonvolatile media, removable media, and/or non-removable media implemented in a method or technology for storage of information, such as computer/machine readable/executable instructions, data structures, program modules, and/or other data. Communication media may embody computer readable instructions, data structures, program modules, or other data and include an information delivery media or system. - An
EEG interface module 206 receives patient information about thepatient 110, such as aEEG and rEEG information associated with the patient's brainwaves. In one embodiment, theEEG sensor 112 includes its own computing device such that theEEG interface module 206 communicates with theEEG sensor 112 via wireless and/or wireline communications. That is, the computing device of theEEG sensor 112 may have one or more processors and volatile and/or non-volatile memory. Examples of such a remote computing device may include one or more personal computers, mobile computers and/or other mobile devices, and other computing devices. In another embodiment, theEEG interface module 206 may receive patient information directly using telemetry information from sensors configured in theNNS entrainment system 108 or a module thereof. - An NNS entrainment
system interface module 207 communicates with theNNS entrainment system 108 to assess and entrain brain activity for controlling respiration, mastication, or other neuromuscular functions of the patient. Additional details related to theNNS entrainment system 108 are disclosed in U.S. patent application Ser. No. 13/457,059, entitled “Enhanced therapeutic stimulus system and methods of use,” filed Apr. 26, 2012; U.S. patent application Ser. No. 13/457,203, entitled “Enhanced Therapeutic Stimulus For Non-Nutritive Suck Entrainment System and Method,” filed Apr. 26, 2012; and U.S. patent application Ser. No. 13/457,154, entitled “Methods of Using An Enhanced Therapeutic Stimulus for Non-Nutritive Suck Entrainment System,” filed Apr. 26, 2012; each of which is incorporated herein by reference in its entirety. Although the aEEG/rEEG analysis system is described herein for use with an NNS device or theNNS entrainment system 108, it should be understood that that the aEEG/rEEG analysis system may be used with any other system that performs a therapeutic plan on the patient using processed EEG data. - An aEEG/
rEEG processing module 208 generates aEEG and rEEG information from patient information gathered by theEEG interface module 206. In one embodiment, the aEEG/rEEG processing module 208 generates the aEEG and rEEG information from raw EEG data obtained from theEEG interface module 206. In another embodiment, the aEEG/rEEG processing module 208 processes aEEG/rEEG information generated by theEEG sensor 112. - A
treatment development module 210 develops a therapeutic plan to be used by theNNS entrainment system 108 for correcting and otherwise alleviating an abnormality of thepatient 110. For example, thetreatment development module 210 develops an entrainment procedure for training certain brainwave behavior in the patient. In another example, thetreatment development module 210 may develop a therapeutic plan or protocol to alter cortical activity of thepatient 110. In another example, thetreatment development module 210 may develop a therapeutic plan to quantify and promote cortical adaptation of the patient. - A
neural analysis module 212 generates one or more reports that may be used by personnel, including researchers and healthcare providers, among others, for determining one or more conditions associated with thepatient 110. For example, theneural analysis module 212 may quantify SEF modulation in the EEG spectra of the received aEEG/rEEG information for diagnostic uses. As another example, theneural analysis module 212 may quantify SEF asymmetry of the aEEG/rEEG information for diagnostic purposes. - A
NNS management module 214 manages the overall operation of theNNS entrainment system 108. For example, theNNS management module 214 generates a graphical user interface (GUI) 220 that displays various activities and provides for administrative control of theNNS entrainment system 108 from the neural analysis andtreatment computing device 102. For example, theGUI 220 may display operating characteristics of theNNS entrainment system 108 and receive user input via aninput device 222 for controlling the operation of theNNS entrainment system 108. - It should be appreciated that the modules described herein are provided only as an example of a computing device that may execute the neural analysis and
treatment application 104 according to the teachings of the present invention, and that other computing devices may have the same modules, different modules, additional modules, or fewer modules than those described herein. For example, one or more modules as described inFIG. 2 may be combined into a single module. As another example, certain modules described herein may be encoded and executed on other computing devices, such as the computing device configured in theNNS entrainment system 108. Additionally, one or more of the modules may be stored and executed by the neural analysis andtreatment computing device 102, where data and instructions are transmitted to and from the neural analysis andtreatment computing device 102 and the computing device of theNNS entrainment system 108 to execute their functions. -
FIG. 3 illustrates an example process that may be performed by the neural analysis andtreatment application 104 according to the teachings of the present disclosure. - In
step 302, theapplication 104 receives EEG/aEEG/rEEG information associated with a patient. The EEG/aEEG/rEEG information may be obtained from any suitable source, such as an EEG sensor that obtains aEEG/rEEG information of a preterm infant. In one embodiment, the neural analysis andtreatment application 104 generates the aEEG and rEEG information from raw EEG data obtained from theEEG sensor 112. In another embodiment, the neural analysis andtreatment application 104 processes aEEG/rEEG information that has been generated by theEEG sensor 112. - In
step 304, theapplication 104 processes the received EEG information. In one embodiment, theapplication 104 generates spectral edge frequency (SEF) information from the received EEG/aEEG/rEEG information. Spectral edge frequency, typically expressed as SEF-“X,” identifies the frequency below which “X” percent of the total power of a given signal is located. For example, SEF-90 is defined as the frequency below which 90% of the power in a spectrum resides. In many cases, SEF-90 measurements are thought to reflect cerebral maturation. The observed modulation in the EEG spectra during and after somatosensory stimulation is a reflection of the dynamics of thalamocortical excitation resulting from synchronous volleys of oral mechanoreceptive afferent activity in the maxillary (V2) and mandibular (V3) divisions of the trigeminal nerve evoked by the pulsed pneumatic orocutaneous stimulation. Based on the observed up-regulation of SEF measurements during and immediately after pulsed orocutaneous stimulation, it is presumed that the frequency of electrocortical activity is influenced by trigeminal-thalamo-cortical input bilaterally. The SEF modulation may reflect a form of long-term adaptation (plasticity) that facilitates increased rates cortical activity for several minutes after the stimulus is removed. - The pulsed orocutaneous stimulus delivered to the mechanoreceptor-rich oral apparatus of the preterm infant (e.g., patient) appears to have ecological validity as a salient sensory input, which also provides a safe and comforting experience for the infant. Early experiences, such as incorporating gentle approach to care, light dimming, rest periods, flexed position with appropriate support, and kangaroo care, positively alters brain structure and function, including EEG spectral coherence and neurobehavioral functioning. Somatosensory stimulation plays an important role in brain function and psychomotor development, and is suggested to minimize the risk of developmental disorders among preterm infants. Massage has been shown to be very beneficial to premature infants. Massage applied to the chest, arms, abdomen, legs, back, and face produced an increase in aEEG amplitudes and significantly increased the dominant frequency of δ, α, θ, and β waves in the EEG. The utility of spectral EEG measures is also apparent in somatosensory stimulation interventions. For example, skin-to-skin contact accelerates brain maturation in healthy preterm infants resulting in fewer REMs, more quiet sleep, respiratory regularity, longer cycles, and less spectral β-wave activity.
- In
step 306, the neural analysis andtreatment application 104 generates reports that may be used for diagnosing one or more conditions of the patient. In one embodiment, theapplication 104 determines a level of asymmetry of the aEEG/rEEG information. A challenge in developmental neuroscience is obtaining a complete understanding of structural and functional hemispheric asymmetries in early life. A significant asymmetry in cortical SEF measurements during oral somatosensory stimulation among preterm infants recorded at 32 weeks PMA has been seen. Indeed, there is an abundance of experimental evidence to support anatomic and functional cortical asymmetry in early life to account for SEF asymmetry. Macroscopic left-right differences has been shown to be present from the fetal life and onward. The developmental time scale may also differ between the cerebral hemispheres. Post-mortem studies have shown that the superior frontal gyrus, the superior temporal gyrus, and Heschl's gyrus appear 1 to 2 weeks sooner in the right hemisphere than in the left, whereas other evidence has shown that the plenum temporal and Heschl's gyrus are larger in the left hemisphere in fetuses and infants. Gray and white matter volumes in neonates tend to be larger in the left hemisphere, which is opposite that in adults. An early rightward morphological asymmetry in the fetal brain during the third trimester, and a right temporal sulcus larger than the left has also been reported. Myelination asymmetries have been observed ininfants 3 to 11 months of age with white matter in the right cerebellum/left cerebrum exhibiting slower myelination relative to the left cerebellum/right cerebrum. DTI and spatial localization methods have been used to demonstrate early leftward symmetries in the arcuate fasciculus and corticospinal tract. These results suggest that the early macroscopic geometry, microscopic organization, and maturation of these white matter bundles are related to later functional lateralization. Among the most intriguing lateralized functions in humans are hand preference and speech-language function. Preterm infants born more than 30 weeks gestational age (GA) exhibit hemispheric asymmetry at 35 weeks post-conceptional age in the form of right lateralization for functional pitch processing, including both signal detection and discrimination. - In
step 308, the neural analysis andtreatment application 104 develops a therapeutic plan for the patient. In one embodiment, theapplication 104 develops a therapeutic plan to provide cortical adaptation for thepatient 110. Adaptation as used herein refers to response attenuation in response to repeated stimulation. Adaptation has many forms (short-term and long-term) and is apparent in the periphery at the mechanosensitive nerve ending, within spinal cord, brainstem, and thalamic subnuclei, and finally among vast arrays of local circuits within the primary (S1) and secondary (S2) somatosensory cortices. Cortical adaptation to sustained sensory input is regarded as one of the most ubiquitous forms of short-term plasticity. In humans, this mechanism helps to improve our spatial and temporal resolution of sensory events, which in turn nurtures motor learning and aids in the development of categorical perception for higher cognitive and communicative function. Neural adaptation can be observed in either the amplitude or frequency domain. In terms of frequency-following capabilities, the rate of neural response adaptation tends to increase as one proceeds from the periphery to the S1/S2 cortex. For example, using the same pulsed pneumatic orocutaneous stimulus with a Soothie® silicone pacifier provide cortical adaptation in neuromagnetic response magnitude in S1 and S2 in young adults. - A significant after-effect or persistence in SEF adaptation was observed in the preterm infants who received the pulsed orocutaneous stimulation. Use of a controlled somatosensory inputs reveal the emergence of cortical adaptation may serve as a biomarker of brain maturation. In the mature brain, sustained sensory stimulation leads to transformations in the thalamocortical encoding that impact the nature of information conveyed about the sensory stimuli. Changes in mid-layer cortical neuron spiking activity reflect a switch in their role with adaptation, from coincidence detectors (tuned for stimulus detection in a non-adapted state) to integrators (tuned for stimulus discrimination after adaptation). With repetitive stimulation, a dynamic cortical inhibitory mechanism shapes the initial activity into a stimulus-specific spatial pattern of columnar assemblies. Lateral interactions between adjacent columns are the result of intrinsic inhibitory (GABA-ergic) and excitatory effects (glutamate) which lead to a differential modification (across columns) of the membrane potential that can last for as long as several seconds.
- The process described above continues throughout operation of the neural analysis and
treatment system 100. However, when use of the neural analysis andtreatment system 100 is no longer needed or desired the process ends. - Study infants were randomly assigned to two groups, including those who received pulsed orocutaneous stimulation (Treatment group), and those who did not (Control group). The participants included 22 healthy preterm infants (16M/6F), with a mean GA of 28.56 wks (SD=2.06), birthweight of 1229.8 gms (SD=338.40), and PMA of 32.17 wks (SD=1.09) at the time of testing. Parents were consented in accordance with the Santa Clara Valley Medical Center Human Subjects Institutional Review Board approval. Inclusion criteria included those infants having a gestational age of 24-32 weeks, and at least 28 weeks post-menstrual age at the time of enrollment. Exclusion criteria included those infants having chromosomal abnormalities, multiple congenital anomalies, or any major congenital anomalies. Infants with history of severe IVH, necrotizing enterocolitis (e.g., greater than stage III), vocal cord paralysis, seizures, and meningitis, or nippling all feeds at the time of enrollment.
- The primary goal was to determine the effects of highly controlled (pneumatic servo) pulsed orocutaneous stimulation presented during gavage feedings begun at 32 weeks PMA on the modulation of aEEG/rEEG activity in the amplitude domain among medically stable preterm infants monitored in the neonatal intensive care unit (NICU).
- The stimulation was delivered by a servo-controlled pneumatic amplifier (NTrainer System®, Innara Health™, Shawnee, Kans. USA) specially designed to transmit repeating pneumatic pulse trains to the soft tissues of the infant's lips-anterior tongue-intraoral mucosa-jaw through a regular (green) Soothie™ silicone pacifier. This 6-cycle orocutaneous stimulus burst was frequency modulated, consisting of sequential cycle periods of 510, 526, 551, 580, and 626 milliseconds with an intertrain interval of 2 seconds.
-
FIG. 4 illustrates example frequency modulated (FM) somatosensory stimulus bursts as presented to the preterm infants through a pneumatically-charged silicone pacifier. Each burst consists of 6 pulses followed by a 2-second pause period. A servo-controlled microprocessor provides the gating function (top panel) to dynamically ‘charge’ the intraluminal pressure of the silicone pacifier (middle panel) resulting in rapid conformational changes in pacifier geometry (bottom panel). The peak-to-peak displacements associated with these pneumatically charged transitions in the intraluminal pressure is approximately 400 microns with a 10-90% rise/fall time of 31 milliseconds. - The spatiotemporal features of this somatosensory stimulus mimics the synchronous volleys of afference associated with ororhythmic patterning, and thus constitutes an approximation to a physiologically salient somatosensory experience normally encoded by the trigeminal system. The pressure rise-fall time (10-90% intercepts) of each 50 millisecond pulse was 31 milliseconds, and the resultant displacement at the pacifier-lip/tongue tissue interface was approximately 400 microns. Three-minute pneumatic orocutaneous stimulation periods were interleaved with 5.5 minute pause periods, where the pacifier was removed from the infant's mouth.
-
FIG. 5 illustrates an example orocutaneous stimulation schedule that results from the test. Nine sequential data blocks are indicated by P1 through P9 spanning 32 minutes. The pulsed orocutaneous stimulus (NT Stimulus) or the blind ‘sham’ pacifier are presented to the infant during periods P3, P5, and P7. The pacifier apparatus was removed from the baby's mouth during periods P1, P2, P4, P6, P8, and P9. - The control infants received a sham stimulation program in which infants were offered the same type of Soothie pacifier without patterned stimulation (blind pacifier). The staging of a single stimulation session was given concurrently with gavage (e.g., tube-feeding). Up to three such sessions were administered to preterm infants per day according to their 3-hour feed cycles. Infants were swaddled with limbs at midline, and in a quiet-awake to drowsy state during stimulation.
- For EEG recording and signal processing, four neonatal hydrogel sensors were placed in the C3, C4, P3, and P4 positions according to the international 10-20 system for EEG monitoring. Acceptable electrode impedance was less than 10 kiloohm (kΩ). EEG signals were recorded on a BRM3 monitor for up to 4-days beginning at approximately 32 weeks PMA.
FIG. 6 illustrates an example preterm infant with aEEG and pneumatically pulsed stimulation through a regular Philips AVENT BPA-free Soothie silicone pacifier coupled to the digitally-controlled handpiece of the NTrainer System®. EEG signals derived from hydrogel electrodes placed at C3-P3 and C4-P4 were recorded on a bedside aEEG monitor. - The right- and left-side EEG signals were amplified by a factor of approximately five thousand and bandpass-filtered (e.g., first-order high-pass filter at (f, −3 dB @ 1 Hz) and a fourth-order low-pass Butterworth at (f, −3 dB @ 50 Hz)), and digitized at a sampling rate of 256 Hz. Brainz Analyze Research (v1.5) software was used to derive the aEEG maxima/mean/minima, and rEEG amplitude bands (A [0-10 microvolts), B [10-25 microvolts], C [25-50 microvolts], D [50-100 microvolts], and E [>100 microvolts]) at 1-min intervals. These EEG measures were derived from 9 sequential epochs (data blocks), spanning 32 minutes each, and centered over the pneumatic orocutaneous or the blind pacifier ‘sham’ stimulus conditions. A total of 1620 EEG blocks were analyzed among the 22 infants. The average number of orosensory sessions sampled per infant was 8.18 (SE=1.09). Portions of recordings were excluded from analysis if electrode impedance exceeded 10 kΩ, or if there was the presence of movement, electrical noise artifact, or asymmetry of voltage in one channel.
- For statistical analysis, mixed models for repeated measures were used to compare the aEEG and rEEG amplitude measures between four stimulus conditions, including (1) NT ‘ON’ pacifier+pneumatic pulse, (2) NT ‘ON’ control epochs, (3) NT ‘OFF’ blind ‘sham’ pacifier, and (4) NT ‘OFF’ control epochs. Adjusting for the infants' gestational ages and birth weights, mixed models estimated the stimulus effect on each outcome via the use of restricted maximum likelihood estimator and compound symmetric error covariance structure. When the stimulus effect was significant at 0.05 alpha level, pair-wise comparisons of adjusted means were performed using a Bonferroni-corrected p-value. All analyses were conducted using SAS 9.3.
- Regarding the measured aEEG amplitude, the presence of the patterned pneumatic orocutaneous stimulation, and its aftereffects produced a significant reorganization of the EEG recorded from the left and right hemisphere in preterm infants as reflected in aEEG and rEEG amplitude parameters. An example of the bi-hemispheric aEEG sampled from C3-P3 and C4-P4 on a preterm infant (32 weeks PMA).
FIG. 7 illustrates example bi-hemispheric aEEG sampled from C3-P3 and C4-P4 on a preterm infant (32 wks PMA). Indexed events (#56, 58, and 60) represent the onset of 3-minute pulsed orocutaneous stimulation periods interleaved with 5.5 minute no-stimulus periods. As shown, aEEG amplitude modulation is present in the electrophysiological record during somatosensory stimulation. Indexed events at 56, 58, and 60 represent the onset of 3-minute pulsed orocutaneous stimulation periods interleaved with 5.5 minute no-stimulus periods. During pulsed somatosensory stimulation, aEEG modulation at the lower and upper amplitude margins of the electrophysiological record was also present. - In the aEEG domain, stimulus condition yielded significant main effects for aEEG maxima, mean, and minima in the left hemisphere (p<0.0001), and significant main effects for aEEG maxima and mean in the right hemisphere. Stimulus condition was also a significant main effect for the crosshead measures of aEEG maxima and mean. Cortical response asymmetry during patterned orocutaneous stimulation was apparent, with the largest changes in aEEG amplitude measures occurring in the left hemisphere. For example, the blind pacifier condition yielded an average aEEG maxima in left and right hemisphere of 12.89 microvolts and 12.81 microvolts, respectively, whereas the addition of the patterned orocutaneous stimulation yielded an average aEEG maxima of 11.68 microvolts and 13.38 microvolts, respectively (p<0.001). Based on the individual hemispheric and crosshead measures, the presence of the pulsatile oral somatosensory stimulation, distinct from a blind pacifier alone, alters the balance in excitation with significant attenuation of the aEEG in the left hemisphere and facilitation in the right hemisphere. This translates to an interhemispheric difference of 1.7 microvolts during pulsatile oral somatosensory stimulation and only 0.08 microvolts in the presence of a blind pacifier (p<0.001). Behaviorally, the orocutaneous stimulation had a calming effect for preterm infants who began the stimulation period in the quiet-alert state and often transitioned to a drowsy-sleep state.
- Regarding the rEEG amplitude bands, the presence of the patterned pneumatic orocutaneous stimulation produced a significant reorganization of rEEG amplitude bands in both hemispheres.
FIG. 8 illustrates example rEEG amplitude bands sampled from the left hemisphere (C3-P3) in preterm infants during pulsed orocutaneous and blind pacifier stimulation conditions. NT ‘IN’ indicates the pneumatically charged pacifier is in the mouth, NT ‘OUT’ indicates the charged pacifier is out of the mouth, BLIND PAC ‘IN’ indicates the regular Soothie pacifier is in the mouth, and BLIND PAC ‘OUT’ indicates the regular Soothie pacifier is out of the baby's mouth. Statistically significant main and pair-wise comparison effects are summarized in Tables 2 and 3.FIG. 9 illustrates example rEEG amplitude bands sampled from the right hemisphere (C4-P4) in preterm infants during pulsed orocutaneous and blind pacifier stimulation conditions. NT ‘IN’ indicates the pneumatically charged pacifier is in the mouth, NT ‘OUT’ indicates the charged pacifier is out of the mouth, BLIND PAC ‘IN’ indicates the regular Soothie pacifier is in the mouth, and BLIND PAC ‘OUT’ indicates the regular Soothie pacifier is out of the baby's mouth. Statistically significant main and pair-wise comparison effects are summarized inFIGS. 10A and 10B , which illustrate mixed model adjusted means, and Post-hoc pairwise comparison. G1: NT ‘On’ andLevel Level Level Level - Overall, significant proportions of the rEEG shifted from the E and D bands to the C band, with considerably less change observed at the low end of rEEG voltage, including bands A and B. Asymmetry was also observed with the degree of reorganization greater in the left hemisphere.
-
FIG. 11 illustrates example rEEG amplitude bands sampled from the crosshead montage (P3-P4) in preterm infants during pulsed orocutaneous and blind pacifier stimulation conditions. NT ‘IN’ indicates the pneumatically charged pacifier is in the mouth, NT ‘OUT’ indicates the pneumatically-charged pacifier is out of the mouth, BLIND PAC ‘IN’ indicates the regular Soothie pacifier is in the mouth, and BLIND PAC ‘OUT’ indicates the regular Soothie pacifier is out of the baby's mouth. As shown inFIG. 11 , stimulus condition yielded significant main effects for crosshead amplitude bands A (0-10 microvolts, p=0.011), C (25-50 microvolts, p<0.0001), D (50-100 microvolts, p<0.0001), and E (>100 microvolts, p<0.0001). The proportion of rEEG adjusted means in the E and C bands for the blind pacifier condition was 32.17% and 17.13%, respectively. Preterm infants who received the pulsatile orocutaneous stimulation manifest a significant shift in rEEG power from the E band (−26.36%) to the C band (+24.86%). A persistence or ‘after-effect’ in the reorganization of the rEEG power banding was observed during the 5.5-minute no-stimulus epochs that followed each of the 3-minute orocutaneous stimulation periods. This after-effect was also significantly different between the blind pacifier and pulsatile oral somatosensory stimulation condition (p<0.0001). A detailed listing of pair-wise comparisons of adjusted means is given inFIG. 10B . Thus, the 3-minute pulsed somatosensory stimulation epochs served to enhance rEEG band C activity while suppressing higher voltage in rEEG bands D and E. Preterm infants exposed to the pulsed orocutaneous stimulation yielded a greater proportion of band C activity throughout the 23-minute recording period that followed the first stimulus block when compared to the blind pacifier condition. -
FIG. 12 illustrates Mean aEEG measures (maxima, mean, and minima) sampled from the left hemisphere (C3-P3) in preterm infants during pulsed orocutaneous (NT ‘ON’) and blind pacifier (PACIFIER only) stimulation conditions. -
FIG. 13 illustrates Mean aEEG measures (maxima, mean, and minima) sampled from the right hemisphere (C4-P4) in preterm infants during pulsed orocutaneous (NT ‘ON’) and blind pacifier (PACIFIER only) stimulation conditions. - Those skilled in the art will appreciate that variations from the specific embodiments disclosed above are contemplated by the invention. The invention should not be restricted to the above embodiments, but should be measured by the following claims.
Claims (32)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/330,712 US11096619B2 (en) | 2013-07-12 | 2014-07-14 | Neural analysis and treatment system |
US17/407,979 US20210378581A1 (en) | 2013-07-12 | 2021-08-20 | Neural analysis and treatment system |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361845842P | 2013-07-12 | 2013-07-12 | |
US201361872236P | 2013-08-30 | 2013-08-30 | |
US14/330,712 US11096619B2 (en) | 2013-07-12 | 2014-07-14 | Neural analysis and treatment system |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/407,979 Continuation US20210378581A1 (en) | 2013-07-12 | 2021-08-20 | Neural analysis and treatment system |
Publications (2)
Publication Number | Publication Date |
---|---|
US20150018705A1 true US20150018705A1 (en) | 2015-01-15 |
US11096619B2 US11096619B2 (en) | 2021-08-24 |
Family
ID=52277641
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/330,712 Active 2037-01-27 US11096619B2 (en) | 2013-07-12 | 2014-07-14 | Neural analysis and treatment system |
US17/407,979 Pending US20210378581A1 (en) | 2013-07-12 | 2021-08-20 | Neural analysis and treatment system |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/407,979 Pending US20210378581A1 (en) | 2013-07-12 | 2021-08-20 | Neural analysis and treatment system |
Country Status (1)
Country | Link |
---|---|
US (2) | US11096619B2 (en) |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105956624A (en) * | 2016-05-06 | 2016-09-21 | 东南大学 | Motor imagery electroencephalogram classification method based on space-time-frequency optimization feature sparse representation |
WO2016187130A1 (en) * | 2015-05-15 | 2016-11-24 | The General Hospital Corporation | System and methods for early diagnosis of autism spectrum disorders |
CN106618559A (en) * | 2016-12-06 | 2017-05-10 | 华东师范大学 | AEEG signal image feature reconstruction, representation and extraction method |
US9814426B2 (en) | 2012-06-14 | 2017-11-14 | Medibotics Llc | Mobile wearable electromagnetic brain activity monitor |
CN108324292A (en) * | 2018-03-26 | 2018-07-27 | 安徽大学 | Visual Environment Analysis of Satisfaction method based on EEG signals |
US10130277B2 (en) | 2014-01-28 | 2018-11-20 | Medibotics Llc | Willpower glasses (TM)—a wearable food consumption monitor |
CN109009090A (en) * | 2018-05-08 | 2018-12-18 | 南京伟思医疗科技股份有限公司 | A kind of brain signal figure display methods based on histogram |
US10213157B2 (en) * | 2017-06-09 | 2019-02-26 | Bose Corporation | Active unipolar dry electrode open ear wireless headset and brain computer interface |
JP6627059B1 (en) * | 2019-03-08 | 2020-01-08 | 株式会社ファーストアセント | Content providing system |
WO2020049430A1 (en) * | 2018-09-04 | 2020-03-12 | Johnson & Johnson Consumer Inc. | Apparatus and method for assessing emotion of infants and young children |
CN113476059A (en) * | 2021-06-02 | 2021-10-08 | 南京伟思医疗科技股份有限公司 | Method for judging left-right brain symmetry based on amplitude integrated electroencephalogram |
US11273283B2 (en) | 2017-12-31 | 2022-03-15 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement to enhance emotional response |
US11344256B2 (en) | 2017-02-21 | 2022-05-31 | Bose Corporation | Collecting biologically-relevant information using an earpiece |
US11364361B2 (en) | 2018-04-20 | 2022-06-21 | Neuroenhancement Lab, LLC | System and method for inducing sleep by transplanting mental states |
US11452839B2 (en) | 2018-09-14 | 2022-09-27 | Neuroenhancement Lab, LLC | System and method of improving sleep |
US11717686B2 (en) | 2017-12-04 | 2023-08-08 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement to facilitate learning and performance |
US11723579B2 (en) | 2017-09-19 | 2023-08-15 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement |
US11786694B2 (en) | 2019-05-24 | 2023-10-17 | NeuroLight, Inc. | Device, method, and app for facilitating sleep |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030013981A1 (en) * | 2000-06-26 | 2003-01-16 | Alan Gevins | Neurocognitive function EEG measurement method and system |
US20040059241A1 (en) * | 1997-09-06 | 2004-03-25 | Stephen Suffin | Method for classifying and treating physiologic brain imbalances using quantitative EGG |
US20060009709A1 (en) * | 2004-07-07 | 2006-01-12 | Rautee Riina A | Detection of encephalopathy |
US20080027348A1 (en) * | 2006-06-23 | 2008-01-31 | Neuro Vista Corporation | Minimally Invasive Monitoring Systems for Monitoring a Patient's Propensity for a Neurological Event |
US20090018462A1 (en) * | 2005-10-24 | 2009-01-15 | John Bell | Neurologic System and Associated Methods |
US20100075285A1 (en) * | 2008-09-22 | 2010-03-25 | KC BioMediX, Inc. | Method and apparatus for a non-nutritive suck entrainment pulse generator |
US20100286549A1 (en) * | 2007-12-18 | 2010-11-11 | New York University | System and Method for Assessing Efficacy of Therapeutic Agents |
US8190249B1 (en) * | 2005-08-01 | 2012-05-29 | Infinite Biomedical Technologies, Llc | Multi-parametric quantitative analysis of bioelectrical signals |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8979896B2 (en) * | 2004-08-30 | 2015-03-17 | University Of Kansas | Pacifier System for stimulating and entraining the human orofacial system |
EP2526500A2 (en) * | 2010-01-18 | 2012-11-28 | Elminda Ltd. | Method and system for weighted analysis of neurophysiological data |
EP2587264A1 (en) * | 2011-10-25 | 2013-05-01 | InfanDx AG | Method and use of metabolites for the diagnosis and differentiation of neonatal encephalopathy |
-
2014
- 2014-07-14 US US14/330,712 patent/US11096619B2/en active Active
-
2021
- 2021-08-20 US US17/407,979 patent/US20210378581A1/en active Pending
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040059241A1 (en) * | 1997-09-06 | 2004-03-25 | Stephen Suffin | Method for classifying and treating physiologic brain imbalances using quantitative EGG |
US20030013981A1 (en) * | 2000-06-26 | 2003-01-16 | Alan Gevins | Neurocognitive function EEG measurement method and system |
US20060009709A1 (en) * | 2004-07-07 | 2006-01-12 | Rautee Riina A | Detection of encephalopathy |
US8190249B1 (en) * | 2005-08-01 | 2012-05-29 | Infinite Biomedical Technologies, Llc | Multi-parametric quantitative analysis of bioelectrical signals |
US20090018462A1 (en) * | 2005-10-24 | 2009-01-15 | John Bell | Neurologic System and Associated Methods |
US20080027348A1 (en) * | 2006-06-23 | 2008-01-31 | Neuro Vista Corporation | Minimally Invasive Monitoring Systems for Monitoring a Patient's Propensity for a Neurological Event |
US20080033502A1 (en) * | 2006-06-23 | 2008-02-07 | Neurovista Corporation A Delaware Corporation | Minimally Invasive System for Selecting Patient-Specific Therapy Parameters |
US20100286549A1 (en) * | 2007-12-18 | 2010-11-11 | New York University | System and Method for Assessing Efficacy of Therapeutic Agents |
US20100075285A1 (en) * | 2008-09-22 | 2010-03-25 | KC BioMediX, Inc. | Method and apparatus for a non-nutritive suck entrainment pulse generator |
Non-Patent Citations (4)
Title |
---|
Inder et al. Lowered Electroencephalographic Spectral Edge Frequency Predicts the Presence of Cerebral White Matter Injury in Premature Infants. Pediatrics, January 2003, Volume 111/Issue 1. * |
Niemarkt et al. Maturational Changes in Automated EEG Spectral Power Analysis in Preterm Infants. Pediatrics Research (2011) Vol. 70, No. 5. * |
O'Reilly et al. Peak-to-peak amplitude in neonatal brain monitoring of premature infants. Clinical Neurophysiology 123 (2012) 2139-2153. * |
Song et al. Modulation of EEG spectral edge frequency during patterned pneumatic oral stimulation in preterm infants. Pediatric Research (2014) 75, 85-92. * |
Cited By (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9814426B2 (en) | 2012-06-14 | 2017-11-14 | Medibotics Llc | Mobile wearable electromagnetic brain activity monitor |
US10130277B2 (en) | 2014-01-28 | 2018-11-20 | Medibotics Llc | Willpower glasses (TM)—a wearable food consumption monitor |
WO2016187130A1 (en) * | 2015-05-15 | 2016-11-24 | The General Hospital Corporation | System and methods for early diagnosis of autism spectrum disorders |
CN105956624A (en) * | 2016-05-06 | 2016-09-21 | 东南大学 | Motor imagery electroencephalogram classification method based on space-time-frequency optimization feature sparse representation |
CN106618559A (en) * | 2016-12-06 | 2017-05-10 | 华东师范大学 | AEEG signal image feature reconstruction, representation and extraction method |
US11344256B2 (en) | 2017-02-21 | 2022-05-31 | Bose Corporation | Collecting biologically-relevant information using an earpiece |
US10213157B2 (en) * | 2017-06-09 | 2019-02-26 | Bose Corporation | Active unipolar dry electrode open ear wireless headset and brain computer interface |
US11723579B2 (en) | 2017-09-19 | 2023-08-15 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement |
US11717686B2 (en) | 2017-12-04 | 2023-08-08 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement to facilitate learning and performance |
US11478603B2 (en) | 2017-12-31 | 2022-10-25 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement to enhance emotional response |
US11273283B2 (en) | 2017-12-31 | 2022-03-15 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement to enhance emotional response |
US11318277B2 (en) | 2017-12-31 | 2022-05-03 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement to enhance emotional response |
CN108324292B (en) * | 2018-03-26 | 2021-02-19 | 安徽大学 | Indoor visual environment satisfaction degree analysis method based on electroencephalogram signals |
CN108324292A (en) * | 2018-03-26 | 2018-07-27 | 安徽大学 | Visual Environment Analysis of Satisfaction method based on EEG signals |
US11364361B2 (en) | 2018-04-20 | 2022-06-21 | Neuroenhancement Lab, LLC | System and method for inducing sleep by transplanting mental states |
CN109009090A (en) * | 2018-05-08 | 2018-12-18 | 南京伟思医疗科技股份有限公司 | A kind of brain signal figure display methods based on histogram |
WO2020049430A1 (en) * | 2018-09-04 | 2020-03-12 | Johnson & Johnson Consumer Inc. | Apparatus and method for assessing emotion of infants and young children |
US11452839B2 (en) | 2018-09-14 | 2022-09-27 | Neuroenhancement Lab, LLC | System and method of improving sleep |
WO2020183527A1 (en) * | 2019-03-08 | 2020-09-17 | 株式会社ファーストアセント | Content-providing system |
JP6627059B1 (en) * | 2019-03-08 | 2020-01-08 | 株式会社ファーストアセント | Content providing system |
US11786694B2 (en) | 2019-05-24 | 2023-10-17 | NeuroLight, Inc. | Device, method, and app for facilitating sleep |
CN113476059A (en) * | 2021-06-02 | 2021-10-08 | 南京伟思医疗科技股份有限公司 | Method for judging left-right brain symmetry based on amplitude integrated electroencephalogram |
Also Published As
Publication number | Publication date |
---|---|
US11096619B2 (en) | 2021-08-24 |
US20210378581A1 (en) | 2021-12-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210378581A1 (en) | Neural analysis and treatment system | |
Herrero et al. | Breathing above the brain stem: volitional control and attentional modulation in humans | |
US11363981B2 (en) | Methods and systems for therapeutic neuromodulation | |
US20150238104A1 (en) | Device and method for examining a phase distribution used to determine a pathological interaction between different areas of the brain | |
Karunakaran et al. | NIRS measures in pain and analgesia: fundamentals, features, and function | |
EP1854404B1 (en) | Monitoring of the state of the central nervous system of a subject | |
Zhao et al. | Seizure detection: do current devices work? And when can they be useful? | |
US20150141529A1 (en) | Method and Apparatus for Treating Centralized Pain | |
Matuz et al. | Habituation of visual evoked responses in neonates and fetuses: a MEG study | |
Zaccaro et al. | Brain-heart interactions are modulated across the respiratory cycle via interoceptive attention | |
Osińska et al. | Non-invasive Vagus nerve stimulation in treatment of disorders of consciousness–longitudinal case study | |
US20230233121A1 (en) | A method and system for measuring a level of anxiety | |
US20230248294A1 (en) | A method and system for measurement of a level of anxiety combined with and/or correlated with a level of a modified state of consciousness and/or a level of pain | |
Sheridan et al. | Neonatal and fetal response decrement of evoked responses: a MEG study | |
Song et al. | Modulation of EEG spectral edge frequency during patterned pneumatic oral stimulation in preterm infants | |
US20210100491A1 (en) | System for use in improving cognitive function | |
JP2022520211A (en) | Methods and systems for monitoring the level of non-pharmacologically induced modified state of consciousness | |
Espenhahn | The relationship between cortical beta oscillations and motor learning | |
US20230293100A1 (en) | A method and system for monitoring a level of pain | |
EP3918986A1 (en) | A method and system for monitoring a level of modified consciousness and a level of pain | |
Opri | Cortico-Thalamic Neurophysiology and Applications in Humans Affected by Essential Tremor | |
Mouthon | Brain plasticity and sleep in the course of development and after acquired brain injury | |
Illman | Beta Rhythm Modulation in the Evaluation of Cortical Sensorimotor Function | |
Manley | Effects of a Pregnancy Lifestyle Intervention on Emotion Regulation in Infants Responding to a Toy Removal Task at One-Year of Age | |
Dittrichova et al. | Responsiveness to stimulation during paradoxical sleep in infants |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: INNARA HEALTH, INC., KANSAS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BARLOW, STEVEN M., PH.D;STALLING, DAVID L., PH.D;ARON, KENNETH;SIGNING DATES FROM 20140911 TO 20140925;REEL/FRAME:033937/0771 |
|
AS | Assignment |
Owner name: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT, MARYLAND Free format text: CONFIRMATORY LICENSE;ASSIGNOR:UNIVERSITY OF KANSAS LAWRENCE;REEL/FRAME:037021/0159 Effective date: 20151029 Owner name: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF Free format text: CONFIRMATORY LICENSE;ASSIGNOR:UNIVERSITY OF KANSAS LAWRENCE;REEL/FRAME:037021/0159 Effective date: 20151029 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE AFTER FINAL ACTION FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
AS | Assignment |
Owner name: KANSAS BIOSCIENCE AUTHORITY, KANSAS Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:INNARA HEALTH, INC.;REEL/FRAME:061649/0815 Effective date: 20221101 |
|
AS | Assignment |
Owner name: CARDINAL HEALTH, INC., OHIO Free format text: AMENDED AND RESTATED INTELLECTUAL PROPERTY SECURITY AGREEMENT;ASSIGNOR:INNARA HEALTH, INC.;REEL/FRAME:061893/0968 Effective date: 20221104 |
|
AS | Assignment |
Owner name: INNARA HEALTH, INC., KANSAS Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE'S NAME AND PROPERTY TYPE 11234607 PREVIOUSLY RECORDED AT REEL: 061649 FRAME: 0815. ASSIGNOR(S) HEREBY CONFIRMS THE RELEASE OF SECURITY INTEREST.;ASSIGNOR:KANSAS BIOSCIENCE AUTHORITY;REEL/FRAME:063055/0394 Effective date: 20221101 |
|
AS | Assignment |
Owner name: CARDINAL HEALTH 200, LLC, UNITED STATES Free format text: MERGER;ASSIGNOR:INNARA HEALTH, INC.;REEL/FRAME:066216/0658 Effective date: 20230224 |